M etastatic disease will develop in as many as 40% of patients with uveal melanoma, the prognosis of which is poor; the median survival is approximately 6 months. Chemotherapeutics used to treat cutaneous melanoma rarely produce durable responses in patients with uveal melanoma, and new systemic treatments are needed. 1 Interleukin (IL)-1, an endogenous mediator of acute and chronic inflammatory conditions, has demonstrated antitumor activity, including the ability to enhance antitumor immune responses and chemotherapy cytotoxicity and to inhibit tumor migration and invasion. [2] [3] [4] There is accumulating evidence, however, that both IL-1 isoforms (IL-1␣ and IL-1␤) may play roles in tumor development, invasion, angiogenesis, and metastases, either directly or indirectly through the induction of other cytokines (see Ref. 5 for review). IL-1 may also contribute to the ability of tumors to escape immune surveillance by promoting M2-polarized macrophages and myeloid-derived suppressor cells (MDSC). 6 -9 Although several studies support inhibiting IL-1 in cancer therapy, little information is available regarding the role of IL-1 in uveal melanoma. During inflammatory responses in the eye, IL-1 is produced by macrophages and corneal cells and promotes a number of processes that may be tumor promoting, including angiogenesis. 10 Among the transcripts found to be upregulated in the progression from intraocular to metastatic uveal melanoma was that of the IL-1 receptor. 11 There is also evidence that providing IL-1 may be therapeutic in uveal melanoma. IL-1 has been shown to inhibit uveal melanoma migration and invasion. 4 Gene expression for the IL-1 receptor accessory protein essential for IL-1 signaling is underexpressed in uveal melanoma manifesting monosomy 3, which is associated with metastasis. 12 Moreover, there is evidence that IL-1 also does not promote, but rather abrogates, the immune-privileged nature of the ocular environment implicated in protecting uveal melanoma from destruction by immune effectors. 13 A naturally occurring IL-1 antagonist, IL-1ra, competitively blocks IL-1␣ and IL-1␤ at the receptor level. A human recombinant IL-1ra is used clinically to treat patients with rheumatoid arthritis, and its application to many ocular inflammatory diseases is also under investigation. 14 -16 Human recombinant IL-1ra has been shown to inhibit the development and growth of metastases in several animal tumor models, including mouse B16 melanoma and human cutaneous melanoma xenografts. 9, [17] [18] [19] [20] Anti-inflammatory drugs are being tested to lessen the toxicity of plaque radiotherapy in patients with uveal melanoma. 21 Given this and the potential contradictory roles of IL-1, we examined the effects of IL-1ra in two established uveal melanoma models, the highly invasive/aggressive MUM2B model and the poorly invasive/aggressive OCM1 model (see Ref. 22 for review). We focused on the modulation of tumor vascularity and myeloid suppressor cell populations.
MATERIALS AND METHODS

Cell Lines and Animals
MUM2B and OCM1 human uveal melanoma cell lines were maintained in Dulbecco's modified Essential medium (DMEM) with 10% heatinactivated fetal calf serum, 1 mM sodium pyruvate, 100 U/mL penicillin, and 100 g/mL streptomycin (Mediatech, Herndon, VA). 23 The cultures were grown at 37°C in 5% CO 2 to confluence, passaged by treatment with 0.05% trypsin in EDTA at 37°C, and washed in media before being centrifuged at 200g for 10 minutes to form a pellet. Athymic NCR male nu/nu mice 4 to 6 weeks of age were obtained from Taconic Farms (Hudson, NY) and were fed a commercial diet and water ad libitum. All experimental procedures on the animals were performed according to the ARVO Statement for the Use of Animals in 
Reagents
Human recombinant IL-1ra (Amgen, Thousand Oaks, CA), IL-1␤ (eBiosciences, Inc., San Diego, CA), and temozolomide (Schering Corporation, Kenilworth, NJ) were purchased.
Tumor Model
Tumors were established by injecting 10 7 tumor cells in 100 L serum-free DMEM subcutaneously into a flank. IL-1ra was administered intraperitoneally. Tumor size was measured bidimensionally with calipers every 2 to 3 days, and tumor volume was calculated by the formula (length ϫ width 2 ) Ϭ 2. Mice were euthanatized when tumors reached 2000 mm 3 . 
Cell Proliferation
Flow Cytometry
Cells were washed twice in PBS/1% bovine serum albumin plus 0.05% sodium azide and stained for 30 minutes on ice with phycoerythrinconjugated monoclonal antibodies specific for CD11b and Gr1 (BD Biosciences, San Jose, CA). Cells were first preincubated for 20 minutes with rabbit IgG blocking buffer to mask nonspecific binding sites and then further incubated with the indicated antibodies or an isotype control antibody for 30 minutes at 4°C. The cells were subsequently washed with PBS containing 2% FBS and fixed with 1% buffered formalin in PBS. Cells were then analyzed by two-color flow cytometry using a flow cytometer (EPICS Altra; Beckman Coulter, Fullerton, CA), as previously described.
23
Tumor RNA
RNA from cell lines in vitro was obtained using a purification method (RNeasy; Qiagen, Valencia, CA) according to the manufacturer's instructions. Dissected tumors grown in vivo were placed in tissue storage reagent (RNAlater; Ambion, Austin, TX) and stored at 4°C. RNA was then extracted (RNeasy; Qiagen) and stored at Ϫ80°C.
Quantitative Real-Time Polymerase Chain Reaction
RNA was analyzed with a PCR system (ABI 7500 Fast Real-Time PCR; Applied Biosystems, Foster City, CA) as previously described. 23 Prestandardized primers and probes (TaqMan; Applied Biosystems) for human IL-1␤, IL-6, tumor necrosis factor (TNF)-␣, transforming growth factor (TGF)-␤, and vascular endothelial growth factor (VEGF) and for mouse IL-1␤, IL-6, IL-12(p40), TNF-␣, VEGF, arginase (Arg1), CD206 (Mrc1), and CXCL10 were used. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), human or mouse, was used as the endogenous control. Reverse transcription and PCR were accomplished using a one-step protocol and a mix (TaqMan Universal Master Mix; Applied Biosystems). C t values were determined, and the relative number of copies of mRNA (RQ) was calculated using the ⌬⌬C t method. Differences in RQ of 0.5 log were considered significant.
Enzyme-Linked Immunosorbent Assay
ELISA kits (R&D Systems, Minneapolis, MN) were used to assay the production of IL-1␤ , IL-6, TGF-␤, TNF-␣ , and VEGF according to the methods recommended by the manufacturer.
Immunohistochemistry
Standard techniques using antibodies to mouse CD11b, CD31, CD140b, (BD Biosciences), ␣-smooth muscle actin (ASMA; Invitrogen, Carlsbad, CA), and biotinylated secondary rabbit antibody (anti-rat IgG), followed by streptavidin-biotin peroxidase complex, were used. 23 Periodic acid Schiff (PAS) staining was performed using published methods that involve staining tumor sections with PAS reagent without hematoxylin staining. 24 The intensity of immunohistochemical reactions was determined with a digital imaging system (Image Analysis System; Leica, Wetzlar, Germany), and the results were quantified (Image Pro, version 6.2; Media Cybernetics, Bethesda, MD), as previously described. 23 Images of 10 representative fields were captured with a charge-coupled device camera (Retiga EXi Fast 1394; QImaging, Surrey, BC) connected to a microscope (DMI 4000B; Leica) at a magnification of ϫ100 and saved as TIFF files (QWin Plus version 3 software; Leica). Images were analyzed (Image-Pro Plus version 6.2 software; Media Cybernetics) using the count/size function. Positive staining in each image was measured, and its ratio to total area of each image was calculated and expressed as mean relative stain area Ϯ SD.
Statistical Analysis
Standard error of the mean (SEM) or standard deviation (SD) for each set of measurements was calculated and represented as y-axis error bars on each graph. Tumor volume data were analyzed using ANOVA. Dose-effect graphs were generated using dose effect analyzer software (CalcuSyn; Biosoft, Ferguson, MO). Synergy or antagonism was also determined (CalcuSyn; Biosoft), quantified by the combination index (CI). 25 CI ϭ 1 indicates an additive effect, CI Ͻ 1 indicates synergy, and CI Ͼ 1 indicates antagonism. Results are reported for the mutually exclusive assumption of modes of activity; however, applying the alternative assumption showed the same results. Other parameters were analyzed with two-sided Student's t-test. P Ͻ 0.05 was considered statistically significant. 
RESULTS
IL-1ra Does Not Directly Affect Uveal Melanoma Proliferation or Cytokine Production In Vitro but Does Inhibit Growth In Vivo
IL-1 affects tumor vascularity and myeloid suppressor cells both directly and indirectly through the induction of several cytokines. 5, 8 The expression of IL-1 and other cytokines implicated in the development of tumor vascularity and myeloid suppressor cells was examined first (Fig. 1) . The aggressive MUM2B cell lines produced more IL-1␤ as well as IL-6, TGF-␤, and TNF-␣. In contrast, the nonaggressive OCM1 cells produced more VEGF (Fig. 1A) . Exposure to IL-1ra in vitro had no effects on the production of these cytokines. As a control for these studies, tumor cells were also exposed to IL-1 in vitro. This resulted in up to log-fold increases in IL-6 and TNF-␣ in both cell lines; VEGF expression was not altered (Fig. 1B) .
Cells were cultured with a range of concentrations of IL-1 and IL-1ra in vitro to examine effects on proliferation (Fig. 2) . IL-1 has been shown to sensitize tumors to the cytotoxic effects of several cytotoxic chemotherapeutics in vitro, 3 and cells were also cultured with the combination of IL-1 or IL-1ra and the chemotherapeutic, temozolomide. IL-1 and IL-1ra did not manifest antiproliferative activity against either cell line. As had been previously observed, only MUM2B, which did not express O6-methylguanine-DNA-methyltransferase, demonstrated sensitivity to temozolomide. 23 CI values were approximately 1, indicating that neither IL-1 nor IL-1ra altered the activity of temozolomide.
The effects of IL-1ra on tumor growth in vivo were then examined (Fig. 3) . A dose and schedule of IL-1ra that is effective in mouse arthritis models and that mimics current clinical application were administered. 26 Substantial MUM2B tumor growth inhibition was observed and compared with that in untreated controls (P ϭ 0.001). OCM1 tumor growth was inhibited compared with that in untreated controls (P ϭ 0.02), but not to the extent seen in MUM2B (P ϭ 0.02).
IL-1ra Modifies Uveal Melanoma Stroma In Vivo
Given the lack of direct antitumor activity in vitro, studies were performed to examine the possibility that antitumor activity of IL-1ra in vivo was indirect and mediated by effects on tumor stroma. Standard immunohistochemical techniques were used to examine the effects in vivo of IL-1ra on the cellular infiltrate of uveal melanoma tumors (Fig. 4A) . The stroma of MUM2B and OCM1 tumors varied with MUM2B, demonstrating greater infiltration of CD11b ؉ macrophages, CD31 ؉ blood vessels, CD140b ؉ fibroblasts and pericytes, and ASMA ؉ pericytes, which are cells implicated in sustaining tumor growth (all P Ͻ 0.05). The frequency of CD11b ϩ cells significantly decreased intratumorally in both MUM2B and OCM1 tumors in response to IL-1ra (P Ͻ 0.01). Decreases in other cell types were not significant. As had been previously noted, on PAS staining MUM2B xenografts exhibited randomly oriented staining with many cross-linking parallel channels and some loops (Fig. 4B) . 27 IL-1ra treatment decreased this staining pattern. The OCM1 tumors showed no PAS staining or some perivascular staining around normal vessels, but IL-1ra had no effect on this staining pattern.
The effects of IL-1ra on the expression of intratumoral cytokines in vivo were examined (Fig. 5) . The dose and schedule of IL-1ra applied as described were used, and the human, tumorderived cytokines were examined in vitro (Fig. 1) were evaluated. The stroma of the xenografts studied was mouse-derived; to examine the changes in the stroma, mouse IL-1␤, IL-6, TGF-␤, TNF-␣, and VEGF production were also examined. Expression of tumorderived cytokine mRNA in vivo paralleled those observed in vitro. MUM2B tumors were characterized by Ͼ0.5 log more (human) IL-1, IL-6, TGF-␤, and TNF-␣ transcripts. OCM1 tumors were characterized by Ͼ0.5 log more (human) VEGF. Although in vitro IL-1ra had no direct effect on human uveal melanoma cell cytokine production (Fig. 1) , in vivo it decreased the expression of mouse IL-1␤, IL-6, and TNF-␣ ( Fig. 5; all P Ͻ 0.05). VEGF levels, however, were not significantly altered.
IL-1ra Decreases Uveal Melanoma-Associated Myeloid Suppressor Cells
The effects of IL-1ra on intratumoral myeloid suppressor cell activity in vivo were examined using a PCR-based method. (Fig. 6A) . Both the decreases in arginase, a product of MDSC and M2-polarized macrophage, 28, 29 and CD206, a marker of M2-polarization, 30 and the increases in IL-12(p40) and in CXCL10, markers of M1-polarization, 30 observed in response to IL-1ra (all P Ͻ 0.05) were consistent with a decrease in MDSC and M2 macrophage polarization and an increase in M1 polarization. Whether IL-1ra could modulate systemic CD11b ϩ Gr1 ϩ MDSC was also examined. The initial studies were performed using spleens harvested at day 10 from mice with MUM2B and OCM1 tumors established as described. These spleens did not manifest a significant increase in the frequency of MDSC, and IL-1ra treatment, using the same dose and the 5-day schedule, had no effect (data not shown). A similar study was then performed harvesting tumors at day 17 after the 5-day course of IL-1ra, when tumors were larger, with volumes Ͼ1000 mm 3 (Fig. 6B ). Increases in splenic MDSC were observed, but only in mice bearing MUM2B tumors. The frequency of splenic MDSC decreased with IL-1ra (P Ͻ 0.001).
DISCUSSION
IL-1 has been shown to play a central role in metastatic tumor growth in cutaneous melanoma. [17] [18] [19] [20] Furthermore, serum concentrations of both isoforms are elevated in patients with high-risk cutaneous melanoma. 31 In uveal melanoma, there is evidence suggesting that IL-1 can both promote and inhibit tumor progression. 4,10 -12 Although a case report did indicate high levels of IL-1␤ in a patient, the clinical significance of IL-1 production in uveal melanoma is not known. 32 We studied uveal melanoma models and found that IL-1 may play a role in tumor progression. Inhibiting IL-1 with IL-1ra inhibits uveal melanoma tumor growth, modifies the tumor stroma and immune response (myeloid suppressor cell populations in particular), and may have a role in treatment.
We found that the more aggressive and metastatic uveal melanoma cells (MUM2B) produced more IL-1 than the less aggressive primary cells (OCM1). MUM2B also produced more IL-6 and TNF-␣, other cytokines implicated in the progression of uveal melanoma. 33 IL-1ra had no effect on the production of these cytokines by the tumor cells, either in vitro (Fig. 1 ) or in vivo (Fig. 5) . Unexpectedly, OCM1 cells and tumors, which were less vascular than MUM2B, produced more VEGF, another cytokine implicated in uveal melanoma progression. 34 Levels of VEGF were not altered by IL-1ra. IL-1 may serve as an autocrine growth factor for some tumors, and IL-1ra has been shown to directly inhibit the proliferation of a mouse skin carcinoma. 35, 36 In contrast, IL-1ra has been shown to block the IL-1-mediated reduction in growth in vitro of human prostatic and hepatic carcinoma and glioblastoma cells. [37] [38] [39] We did not observe any direct effects of IL-1ra on uveal melanoma cell proliferation in vitro. These results parallel a previous report evaluating two anti-inflammatory steroids, triamcinolone acetonide and anecortave acetate, which also had no effect on the growth or production of VEGF by human uveal melanoma cell lines in vitro. 40 Although inactive in vitro, IL-1ra did manifest antitumor activity in vivo. This was most evident in the MUM2B model, which produced more IL-1. It should be noted that there is extensive sequence homology between mouse and human IL-1, and mouse and human IL-1 show cross-species activities. 41, 42 IL-1ra decreased PAS ϩ loops, networks lacking endothelium termed vasculogenic mimicry, that have previously been identified in uveal melanoma, including MUM2B tumors, and other cancer types. IL1B was one of the genes found to be upregulated in uveal melanoma-forming networks, which are associated with a poor prognosis, in a gene array study. 43 Inhibitors of matrix metalloproteinase and cadherin have been shown to inhibit the formation of these loops in uveal melanoma models. 44 -47 In an in vitro breast cancer model, the anti-inflammatory cyclo-oxygenase (COX)-2 inhibitor celecoxib was shown to inhibit PAS ϩ vasculogenic mimicry. 48 We did not observe significant changes in the blood vessels of macroscopic tumors. When applied in the setting of microscopic tumors, IL-1ra has been shown to reduce vascularization. 19 We did not observe effects on tumor blood vessel density or in tumor- infiltrating fibroblasts and pericytes when IL-1ra was applied in the setting of established, macroscopic tumor. Furthermore, we did not observe the decrease in tumor VEGF production in vivo previously reported with IL-1ra. 20 Although proinflammatory, IL-1 also promotes M2-polarization and the development of MDSC, which suppress the immune response by a variety of mechanisms. 7, 8 The infiltration of CD11b ϩ CD68 ϩ macrophages in patients with uveal melanoma has been associated with an unfavorable prognosis. 49 -51 An immunosuppressive role of tumor-associated CD11b ϩ cells has been suggested in transplantable uveal melanoma models in mice. 52 It has recently been reported that in aged mice, the outgrowth of intraocular melanoma depends on proangiogenic M2-type macrophages. 53 MDSC have recently been shown to expand in the blood of patients with uveal melanoma. 54 We found that MUM2B tumors were associated with increases in myeloid suppressor cell populations. We observed a decrease in M2 macrophage polarization and MDSC with IL-1ra treatment. This was evident systemically in the MUM2B model, with the decrease in splenic CD11b ϩ Gr1 ϩ MDSC, and intratumorally in both MUM2B and OCM1 models, with the reduced infiltration of CD11b ϩ cells, the reduced levels of arginase and CD206, and the increased levels of IL-12(p40) and CXCL10. The ability of IL-1ra to decrease levels of other cytokines implicated in the generation of myeloid suppressor cell populations, such as IL-6, and TNF-␣, might have contributed to these alterations. Although the expansion and function of MDSC does not require T cells, 55 these xenograft studies do have limitations, and further study in other models will be necessary.
IL-1ra has demonstrated benefits in experimental models of keratitis, corneal neovascularization, conjunctivitis, uveitis, and corneal graft rejection. 14 -16,56 -58 The results of our studies support the testing of IL-1ra in patients with uveal melanoma. Direct antitumor effects and indirect antitumor effects on stroma and immune suppressor mechanisms could potentially be exploited. Other anti-inflammatory drugs, including the nonselective COX inhibitor nepafenac, which is used clinically as an adjunct to cataract surgery, have demonstrated antitumor activity in other uveal melanoma models. 59 Anti-inflammatory drugs are currently being applied clinically in patients with uveal melanoma to lessen the macular edema and retinitis that complicate plaque radiotherapy. 21 IL-1 appears to act relatively "upstream" in the molecular cascade, leading to inflammation and to tumor promotion, and its inhibition by IL-1ra may have clinical applications in patients with uveal melanoma.
